Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
Status:
Completed
Trial end date:
2011-01-03
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the steady-state plasma pharmacokinetics
(PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar
macrophages (AM) of healthy volunteers.